Research Article
Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study
Figure 2
Graphs show the changes in the NYHA classification with different medication doses. For patients on 50 mg, 100 mg, and 200 mg of sacubitril/valsartan daily, the average values were and , and , and and , respectively. In all cases, the value was statistically significant (i.e., below the 0.05 cut-off).